Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report
DNA repair mutations (BRCA1 and BRCA2) are found in metastatic castration-resistant prostate cancer (CRPC) patients. Here, we report a case of a 71-year-old male patient with metastatic CRPC along with BRCA2 and PTEN mutations. As per the genomic findings of the Foundation One report, FDA-approved t...
Main Authors: | Pramod Kumar Julka, Amit Verma, Kush Gupta |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-02-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/505182 |
Similar Items
-
Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review
by: Dongsheng Zhao, et al.
Published: (2023-05-01) -
Multi-Gene Next-Generation Sequencing Panel for Analysis of <i>BRCA1</i>/<i>BRCA2</i> and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer
by: Thais Maloberti, et al.
Published: (2023-05-01) -
Targeted Approaches in Metastatic Castration-Resistant Prostate Cancer: Which Data?
by: Claudia Mosillo, et al.
Published: (2022-08-01) -
BRCA2 reversion mutation confers resistance to olaparib in breast cancer
by: Shinya Yamamoto, et al.
Published: (2023-06-01) -
Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials
by: Zhanyang Luo, et al.
Published: (2023-10-01)